The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

Semaglutide's FDA approval for preventing heart ... showing efficacy in diverse patient subgroups. High serum vitamin B12 concentrations correlate with increased all-cause mortality risk ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Ozempic is an FDA-approved medication for treating type 2 diabetes. Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that acts like the GLP-1 hormone ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

The value proposition in contemporary health and disease care: A study published in the Canadian Journal of Cardiology into the cost-effectiveness of the use of semaglutide in overweight or obese ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like ...

Single injection of ProLynx long-acting semaglutide produced 20% weight loss in diet-induced obese mice, which is comparable to multiple semaglutide injections over the same period The paper ...